Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
References |
: Endoh T, Yagihashi A, Sasaki M, Watanabe N. Ceftizoxime-induced hemolysis due to immune complexes: case report and determination of the epitope responsible for immune complex-mediated hemolysis. Transfusion. 1999 Mar;39(3):306-9. PubMed PMID: 10204595.
|
---|
Molecular Formula |
C10H12N2O5S
|
---|---|
Molecular Weight |
272.27
|
Exact Mass |
272.046
|
CAS # |
957-68-6
|
Related CAS # |
957-68-6
|
Appearance |
Solid powder
|
Density |
1.6±0.1 g/cm3
|
Boiling Point |
560.6±50.0 °C at 760 mmHg
|
Melting Point |
>300 °C(lit.)
|
Flash Point |
292.9±30.1 °C
|
Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
Index of Refraction |
1.661
|
LogP |
-0.8
|
SMILES |
CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)N)SC1)C(=O)O
|
InChi Key |
HSHGZXNAXBPPDL-HZGVNTEJSA-N
|
InChi Code |
InChI=1S/C10H12N2O5S/c1-4(13)17-2-5-3-18-9-6(11)8(14)12(9)7(5)10(15)16/h6,9H,2-3,11H2,1H3,(H,15,16)/t6-,9-/m1/s1 SMILES
|
Chemical Name |
(6R,7R)-3-(Acetyloxymethyl)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
Synonyms |
7-ACS 7 ACS 7ACS 7-Aminocephalosporinic acid 7 Aminocephalosporinic acid 7Aminocephalosporinic acid
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
Ethanol : ~1.1 mg/mL (~4.04 mM)
H2O : ~1.1 mg/mL (~4.04 mM) DMF :< 1 mg/mL DMSO :< 1 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 1 mg/mL (3.67 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.6728 mL | 18.3641 mL | 36.7282 mL | |
5 mM | 0.7346 mL | 3.6728 mL | 7.3456 mL | |
10 mM | 0.3673 mL | 1.8364 mL | 3.6728 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02351310 | WITHDRAWN | Drug: Betamethasone Genetic: Placebo |
Premature Birth Preterm Labor |
Pediatrix | 2015-11 | Phase 3 |
NCT00635102 | COMPLETEDWITH RESULTS | Drug: D-Cycloserine PO and Glycine IV Drug: Placebo D-Cycloserine PO and placebo Glycine IV Drug: Placebo D-Cycloserine PO and Glycine IV Drug: D-Cycloserine PO and placebo Glycine IV |
Alcohol Dependence | Yale University | 1997-10 | Not Applicable |
NCT04000490 | COMPLETED | Other: SCARE Score | ACS - Acute Coronary Syndrome Assessment Chest Pain |
Centre Hospitalier Régional d'Orléans | 2019-10-01 | |
NCT05385341 | WITHDRAWN | Other: Telerehabilitation (Tele RCV) Other: Rehabilitation (RCV) |
Acute Coronary Syndrome | University Hospital, Toulouse | 2022-09-01 | Not Applicable |
NCT02580773 | COMPLETED | Drug: Prophylactic anticoagulation ( INNOHEP®) Drug: Curative anticoagulation ( INNOHEP®) |
Acute Chest Syndrome Anemia Low-Molecular-Weight Heparin Sickle Cell Locations |
Assistance Publique - Hôpitaux de Paris | 2016-12-16 | Phase 3 |